Article
BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Pediatric blood & cancer - 1 May 2018
Chisholm Julia C, Suvada Jozef, Dunkel Ira J, Casanova Michela, Zhang Weijiang, Ritchie Natasha, Choi YounJeong, Park Jane, Das Thakur Meghna, Simko Stephen, Wan Rachel Tam Nga, Ferrari Andrea
Abstract excerpt
BACKGROUND: Vemurafenib, a selective inhibitor of BRAF kinase, is approved for the treatment of adult stage IIIc/IV BRAF V600 mutation-positive melanoma. We conducted a phase I, open-label, dose-escalation study in pediatric patients aged 12-17 years with this tumor type (NCT01519323). PROCEDURE: Patients received vemurafenib orally until disease progression. Dose escalation was conducted using a 3 + 3 design....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.